FTD/TPI
4 abstracts
Abstract
Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial.Org: Université Paris-Cité (Paris Descartes), Georges Pompidou European Hospital, SIRIC CARPEM, Taiho Oncology Inc., Servier International Research Institute,
Abstract
A phase 2 study of trifluridine/tipiracil (FTD/TPI) in recurrent/metastatic nasopharyngeal (r/m NPC) carcinomas with or without prior exposure to fluoropyrimidines.Org: National University Health Systems,
Abstract
Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines.Org: Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Saw Swee Hock School of Public Health, National University of Singapore,
Abstract
Prospective evaluation of factors associated with acceptance of feeding tube (FT) placement and clinical outcomes during radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinoma (HNSCC).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Centre Henri Becquerel, Centre H. Becquerel, Cancer Centre Henri Becquerel, Rouen, France,